Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.
Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.
The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.